Cargando…

A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014–2022)

Background: The REFLECT phase-III trial has demonstrated the efficacy of lenvatinib in improving the overall survival of advanced hepatocellular carcinoma (HCC) patients, comparable to sorafenib. The rapidly evolving landscape of hepatocellular carcinoma therapy presents new avenues for lenvatinib....

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Cong-Cong, Yu, Cai-Yan, Zhang, Jing, Wang, Rui, Kong, Xiang-Shuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301759/ https://www.ncbi.nlm.nih.gov/pubmed/37388443 http://dx.doi.org/10.3389/fphar.2023.1159286

Ejemplares similares

Clinical study of lenvatinib in the treatment of hepatitis virus-related hepatocellular carcinoma and antiviral therapy
por: Li, Xiaomi, et al.
Publicado: (2023)

Trends in volume-regulated anion channel (VRAC) research: visualization and bibliometric analysis from 2014 to 2022
por: Liu, Tianbao, et al.
Publicado: (2023)

Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma
por: He, Ying, et al.
Publicado: (2023)

Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients
por: Liu, Juanfang, et al.
Publicado: (2021)

Case report: Remarkable response to sintilimab, lenvatinib, and nab-paclitaxel in postoperative metastatic chemotherapy-resistant combined hepatocellular-cholangiocarcinoma
por: Zhou, Nan, et al.
Publicado: (2023)

A bibliometric analysis of complement in IgA nephropathy from 1991 to 2022
por: Guo, Yun, et al.
Publicado: (2023)

Lenvatinib resistance mechanism and potential ways to conquer
por: Bo, Wentao, et al.
Publicado: (2023)

Efficacy of lenvatinib combined with sequential transarterial chemoembolization for primary hepatocellular carcinoma and the effects on serum basic fibroblast growth factor and vascular endothelial growth factor
por: Xie, Qing-Yun, et al.
Publicado: (2022)

Bibliometric and visual analysis in the field of traditional Chinese medicine in cancer from 2002 to 2022
por: Bai, Facheng, et al.
Publicado: (2023)

Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapy
por: Guo, De-Zhen, et al.
Publicado: (2023)

Application and Resistance Mechanisms of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
por: Tao, Meng, et al.
Publicado: (2023)

Bibliometric analysis and visualization of research trends on HIV-1 capsid inhibitors (2000–2022)
por: Sun, Lin, et al.
Publicado: (2023)

Chelidonine enhances the antitumor effect of lenvatinib on hepatocellular carcinoma cells
por: Hou, Fang-jie, et al.
Publicado: (2019)

Differences in the pharmacokinetics and steady-state blood concentrations of orally administered lenvatinib in adult and juvenile rats
por: Du, Xiaoyue, et al.
Publicado: (2023)

Research landscape and frontiers of non-alcoholic steatohepatitis-associated hepatocellular carcinoma: a bibliometric and visual analysis
por: Gao, Bowen, et al.
Publicado: (2023)

YRDC Mediates the Resistance of Lenvatinib in Hepatocarcinoma Cells via Modulating the Translation of KRAS
por: Guo, Jun, et al.
Publicado: (2021)

Research hotspots and frotiers of stem cells in stroke: A bibliometric analysis from 2004 to 2022
por: Zhang, Qi, et al.
Publicado: (2023)

Bibliometric and visualization analysis of kidney repair associated with acute kidney injury from 2002 to 2022
por: Li, Jun, et al.
Publicado: (2023)

Lenvatinib for Hepatocellular Carcinoma: A Literature Review
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma
por: Lee, Matthew Man Pok, et al.
Publicado: (2023)

Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
por: Zhao, Shu, et al.
Publicado: (2022)

Research trends and hotspots on the links between caveolin and cancer: bibliometric and visual analysis from 2003 to 2022
por: Tan, Yaqian, et al.
Publicado: (2023)

Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy
por: Guo, De-Zhen, et al.
Publicado: (2023)

Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma
por: Wang, Yan-Yu, et al.
Publicado: (2023)

The Therapeutic Efficacy and Safety of Compound Kushen Injection Combined with Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma: An Update Systematic Review and Meta-Analysis
por: Ma, Xiao, et al.
Publicado: (2016)

Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma
por: He, Min-Ke, et al.
Publicado: (2021)

Synergistic Effect of Lenvatinib and Chemotherapy in Hepatocellular Carcinoma Using Preclinical Models
por: Wang, Mingxun, et al.
Publicado: (2023)

Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
por: Personeni, Nicola, et al.
Publicado: (2019)

Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2021)

Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma
por: Amioka, Kei, et al.
Publicado: (2022)

Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma
por: Prasoppokakorn, Thaninee, et al.
Publicado: (2022)

Lenvatinib applicability in the therapeutic strategy of patients with hepatocellular carcinoma
por: Merle, Philippe
Publicado: (2023)

Lenvatinib Combined With a PD-1 Inhibitor as Effective Therapy for Advanced Intrahepatic Cholangiocarcinoma
por: Xie, Lulu, et al.
Publicado: (2022)

Association Between Procalcitonin and Post-hepatectomy Liver Failure in Hepatocellular Carcinoma Patients
por: Li, Yi-Ran, et al.
Publicado: (2021)

TACE Combined with Lenvatinib and Camrelizumab for Unresectable Multiple Nodular and Large Hepatocellular Carcinoma (>5 cm)
por: Xiang, Zhanwang, et al.
Publicado: (2023)

L-carnitine prevents lenvatinib-induced muscle toxicity without impairment of the anti-angiogenic efficacy
por: Jing, Zheng, et al.
Publicado: (2023)

Bibliometric study of immunotherapy for hepatocellular carcinoma
por: Li, Zhiyi, et al.
Publicado: (2023)

The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma
por: Zhu, Jie, et al.
Publicado: (2021)

Machine Learning to Predict the Response to Lenvatinib Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma
por: Ma, Jun, et al.
Publicado: (2023)

Development of a Multivariate Prognostic Model for Lenvatinib Treatment in Hepatocellular Carcinoma
por: Li, Xiaomi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e24nsdh55iemfi0gna0cau5cnf